These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
98 related articles for article (PubMed ID: 1731950)
21. Factor XIIIa cross-links lipoprotein(a) with fibrinogen and is present in human atherosclerotic lesions. Romanic AM; Arleth AJ; Willette RN; Ohlstein EH Circ Res; 1998 Aug; 83(3):264-9. PubMed ID: 9710118 [TBL] [Abstract][Full Text] [Related]
22. Influence of a natural and a synthetic inhibitor of factor XIIIa on fibrin clot rheology. Ryan EA; Mockros LF; Stern AM; Lorand L Biophys J; 1999 Nov; 77(5):2827-36. PubMed ID: 10545380 [TBL] [Abstract][Full Text] [Related]
23. Degradation of cross-linked fibrin by human leukocyte proteases. Francis CW; Marder VJ J Lab Clin Med; 1986 Apr; 107(4):342-52. PubMed ID: 3514776 [TBL] [Abstract][Full Text] [Related]
24. Inhibition of fibrin polymerization by fragment d is affected by calcium, Gly-Pro-Arg and Gly-His-Arg. Furlan M; Rupp C; Beck EA Biochim Biophys Acta; 1983 Jan; 742(1):25-32. PubMed ID: 6824684 [TBL] [Abstract][Full Text] [Related]
25. A unique property of a plasma proteoglycan, the C1q inhibitor. An anticoagulant state resulting from its binding to fibrinogen. Galanakis DK; Ghebrehiwet B J Clin Invest; 1994 Jan; 93(1):303-10. PubMed ID: 8282801 [TBL] [Abstract][Full Text] [Related]
26. Covalent cross-linking of fibronectin to fibrin is required for maximal cell adhesion to a fibronectin-fibrin matrix. Corbett SA; Lee L; Wilson CL; Schwarzbauer JE J Biol Chem; 1997 Oct; 272(40):24999-5005. PubMed ID: 9312106 [TBL] [Abstract][Full Text] [Related]
28. Functional analysis of fibrin {gamma}-chain cross-linking by activated factor XIII: determination of a cross-linking pattern that maximizes clot stiffness. Standeven KF; Carter AM; Grant PJ; Weisel JW; Chernysh I; Masova L; Lord ST; Ariëns RA Blood; 2007 Aug; 110(3):902-7. PubMed ID: 17435113 [TBL] [Abstract][Full Text] [Related]
29. [Equilibrium system consisting of soluble forms of fibrin and the specific anticoagulant D fragment of the firbinogen molecule]. Smekhova KO; Ugarova TP; Pozdniakova TM; Belitser VO Ukr Biokhim Zh; 1977; 49(6):5-11. PubMed ID: 22149 [TBL] [Abstract][Full Text] [Related]
30. Isolation of a fibrin-binding fragment from blood coagulation factor XIII capable of cross-linking fibrin(ogen). Greenberg CS; Enghild JJ; Mary A; Dobson JV; Achyuthan KE Biochem J; 1988 Dec; 256(3):1013-9. PubMed ID: 3066350 [TBL] [Abstract][Full Text] [Related]
31. Characterization of stromelysin 1 (MMP-3), matrilysin (MMP-7), and membrane type 1 matrix metalloproteinase (MT1-MMP) derived fibrin(ogen) fragments D-dimer and D-like monomer: NH2-terminal sequences of late-stage digest fragments. Bini A; Wu D; Schnuer J; Kudryk BJ Biochemistry; 1999 Oct; 38(42):13928-36. PubMed ID: 10529239 [TBL] [Abstract][Full Text] [Related]
32. Clottability and cross-linking reactivity of fibrin(ogen) following differential release of fibrinopeptides A and B. Furlan M; Seelich T; Beck EA Thromb Haemost; 1976 Dec; 36(3):582-92. PubMed ID: 14415 [TBL] [Abstract][Full Text] [Related]
33. The role of fibrinogen D domain intermolecular association sites in the polymerization of fibrin and fibrinogen Tokyo II (gamma 275 Arg-->Cys). Mosesson MW; Siebenlist KR; DiOrio JP; Matsuda M; Hainfeld JF; Wall JS J Clin Invest; 1995 Aug; 96(2):1053-8. PubMed ID: 7635941 [TBL] [Abstract][Full Text] [Related]
34. Crosslinking kinetics of the human transglutaminase, factor XIII[A2], acting on fibrin gels and gamma-chain peptides. Lewis KB; Teller DC; Fry J; Lasser GW; Bishop PD Biochemistry; 1997 Feb; 36(5):995-1002. PubMed ID: 9033388 [TBL] [Abstract][Full Text] [Related]
35. Rapid formation of large molecular weight alpha-polymers in cross-linked fibrin induced by high factor XIII concentrations. Role of platelet factor XIII. Francis CW; Marder VJ J Clin Invest; 1987 Nov; 80(5):1459-65. PubMed ID: 3680507 [TBL] [Abstract][Full Text] [Related]
36. The alternatively spliced V region contributes to the differential incorporation of plasma and cellular fibronectins into fibrin clots. Wilson CL; Schwarzbauer JE J Cell Biol; 1992 Nov; 119(4):923-33. PubMed ID: 1358897 [TBL] [Abstract][Full Text] [Related]
37. [Influence of end products of plasmin-mediated hydrolysis of fibrinogen and fibrin (EF and Ef fragments) on fibrinogen cross-linking]. Leonova VB; Rozenfel'd MA; Biriukova MI; Kostanova EA; Vasil'eva MV Izv Akad Nauk Ser Biol; 2002; (5):522-7. PubMed ID: 12400374 [TBL] [Abstract][Full Text] [Related]
38. Identification of a site in fibrin(ogen) which is involved in the acceleration of plasminogen activation by tissue-type plasminogen activator. Nieuwenhuizen W; Vermond A; Voskuilen M; Traas DW; Verheijen JH Biochim Biophys Acta; 1983 Oct; 748(1):86-92. PubMed ID: 6684481 [TBL] [Abstract][Full Text] [Related]
39. ClfA(221-550), a fibrinogen-binding segment of Staphylococcus aureus clumping factor A, disrupts fibrinogen function. Liu CZ; Shih MH; Tsai PJ Thromb Haemost; 2005 Aug; 94(2):286-94. PubMed ID: 16113817 [TBL] [Abstract][Full Text] [Related]
40. Normal binding of calcium to five fibrinogen variants with mutations in the carboxy terminal part of the gamma-chain. Furlan M; Stucki B; Steinmann C; Jungo M; Lämmle B Thromb Haemost; 1996 Sep; 76(3):377-83. PubMed ID: 8883274 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]